| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 21.61M | 23.84M | 29.52M | 29.91M | 25.49M | 18.22M |
| Gross Profit | 6.05M | 7.11M | 8.84M | 9.42M | 7.11M | 5.20M |
| EBITDA | 2.50M | 2.30M | 6.98M | 8.33M | 6.13M | 3.70M |
| Net Income | 577.92K | 398.17K | 4.60M | 6.24M | 4.59M | 3.03M |
Balance Sheet | ||||||
| Total Assets | 71.58M | 61.77M | 46.56M | 37.26M | 36.41M | 25.20M |
| Cash, Cash Equivalents and Short-Term Investments | 8.89M | 80.47K | 112.82K | 840.86K | 3.61M | 53.11K |
| Total Debt | 8.76M | 7.30M | 4.12M | 5.41M | 3.31M | 5.72M |
| Total Liabilities | 17.68M | 17.42M | 10.57M | 7.16M | 9.88M | 14.18M |
| Stockholders Equity | 53.52M | 43.91M | 35.48M | 29.56M | 26.01M | 10.52M |
Cash Flow | ||||||
| Free Cash Flow | -10.14M | -7.73M | -713.82K | -4.92M | -700.78K | -1.69M |
| Operating Cash Flow | -10.13M | -7.72M | -651.91K | -187.12K | 4.05M | 2.64M |
| Investing Cash Flow | -10.64K | -15.73K | -1.19M | -3.06M | -7.44M | -3.00M |
| Financing Cash Flow | 18.57M | 8.76M | 1.16M | 2.26M | 5.35M | 112.49K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
| ― | $9.65M | 0.62 | 1.32% | ― | -15.44% | -94.04% | |
| ― | $16.83M | -1.22 | -17.98% | ― | 13.83% | -82.27% | |
| ― | $8.99M | ― | ― | ― | ― | ― | |
| ― | $51.40M | -46.17 | -8.34% | ― | 22.79% | 74.00% | |
| ― | $2.21M | -0.18 | -3.22% | ― | -49.19% | -394.71% |
Bon Natural Life Limited announced its unaudited financial results for the six months ended March 31, 2025, revealing a 21.9% decrease in total revenues compared to the same period in 2024. Despite the revenue decline, the company reported a significant increase in income from operations, which rose by 236.1%, and a net income of $169,227, marking a turnaround from a net loss in the previous year. These results indicate improved operational efficiency and profitability, which could positively impact the company’s market positioning and stakeholder confidence.
On September 1, 2025, Bon Natural Life Limited’s subsidiary, Xi’an App-Chem Bio (Tech) Co., Ltd, entered into a Sales Cooperation Agreement with Beijing Huahai Keyuan Technology Co., Ltd. This agreement allows Huahai Keyuan to market and sell Bon’s second-generation Apple Series products in China, aiming for sales of at least $18 million over two years. The products, which combine apple polyphenols with plant proteins, are designed to enhance weight management and metabolic health. This strategic partnership is expected to strengthen Bon’s market position in the nutraceutical sector, leveraging advanced extraction technology to deliver higher bioactivity and meet growing consumer demand for scientifically validated health solutions.